- Home
- EVOK vs INTS Comparison
EVOK vs INTS Comparison
Compare EVOK & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- INTS
- Stock Information
- Founded
- EVOK 2007
- INTS 2012
- Country
- EVOK United States
- INTS United States
- Employees
- EVOK N/A
- INTS N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- INTS Health Care
- Exchange
- EVOK Nasdaq
- INTS Nasdaq
- Market Cap
- EVOK 7.7M
- INTS 7.4M
- IPO Year
- EVOK 2013
- INTS 2023
- Fundamental
- Price
- EVOK $4.43
- INTS $0.33
- Analyst Decision
- EVOK
- INTS Strong Buy
- Analyst Count
- EVOK 0
- INTS 2
- Target Price
- EVOK N/A
- INTS $6.75
- AVG Volume (30 Days)
- EVOK 7.2M
- INTS 4.4M
- Earning Date
- EVOK 08-12-2025
- INTS 08-07-2025
- Dividend Yield
- EVOK N/A
- INTS N/A
- EPS Growth
- EVOK N/A
- INTS N/A
- EPS
- EVOK N/A
- INTS N/A
- Revenue
- EVOK $11,594,083.00
- INTS N/A
- Revenue This Year
- EVOK $57.82
- INTS N/A
- Revenue Next Year
- EVOK $59.12
- INTS N/A
- P/E Ratio
- EVOK N/A
- INTS N/A
- Revenue Growth
- EVOK 89.89
- INTS N/A
- 52 Week Low
- EVOK $1.94
- INTS $0.26
- 52 Week High
- EVOK $12.32
- INTS $4.94
- Technical
- Relative Strength Index (RSI)
- EVOK 53.72
- INTS 44.65
- Support Level
- EVOK $4.26
- INTS $0.30
- Resistance Level
- EVOK $4.73
- INTS $0.35
- Average True Range (ATR)
- EVOK 0.73
- INTS 0.03
- MACD
- EVOK -0.07
- INTS 0.01
- Stochastic Oscillator
- EVOK 25.95
- INTS 49.45
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.